Adam Friedman, MD: Dermatology Treatments Show Promise as COVID-19 Medications

May 11, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

With the majority of the scientific research community focused, a COVID-19 vaccine could be on the horizon.

Never before has so much attention been paid to a coronavirus.

While researchers previously have not had much luck in developing a vaccine for the family of viruses, the majority of the scientific research community has zeroed in on the coronavirus disease 2019 (COVID-19), giving hope that a vaccine is possible sooner rather than later.

With a significant number of vaccines already in clinical trials, there is also ongoing research testing both new and existing drugs that could potentially help patients once they contract the virus.

In an interview with HCPLive®, Adam Friedman, MD, Professor & Interim Chair of Dermatology at The George Washington University School of Medicine and Health Sciences, said because there is so much attention being paid to the virus globally, a vaccine could be on the horizon.

However, the success of any potential vaccine relies on whether or not the virus mutates or changes in the near future.

Friedman, who recently participated in a free online webinar hosted by HCPLive® and sister publication Dermatology Times titled “Derm Clinical Updates: Keeping Up with COVID-19,” also discussed how dermatologists can be essential in the research of existing medications that could be effective in treating COVID-19.